biotech industry
Coverage of biotech industry in the Nexus archive.
- FDA weighs a new kind of flu shot based on technology RFK Jr. has questioned
The FDA is considering Moderna's mRNA-based flu shot, which could be the first of its kind. The decision may impact the biotech industry. The technology has been questioned by RFK Jr.
- FDA weighs a new kind of flu shot based on technology RFK Jr. has questioned
The FDA is set to decide on Moderna's mRNA-based flu shot, potentially the first of its kind, which could significantly impact the biotech industry. The decision involves technology that RFK Jr. has questioned.
- STAT+: Pharmalittle: We’re reading about a fugitive who became a biotech exec, a hospital suing Lilly, and more
A former doctor, using the alias Richard Graydon, evaded detection for two decades while working in the biotech industry. A New Hampshire hospital is suing Eli Lilly over data requirements tied to the 340B drug discount program.
- STAT+: In the biotech industry, a most-wanted fugitive was long hiding in plain sight
A former doctor working under the alias Richard Graydon was discovered to be a fugitive who had been employed in the biotech industry and by pharmaceutical companies for two decades. His fabricated CV, which included achievements in cancer drug development, was not thoroughly vetted by the companies.
- STAT+: At BIO 2026, industry wrestled with Washington politics, and making AI work better
At the 2026 BIO conference in San Diego, biotech and startup executives discussed challenges posed by China's growing influence in drug development, strategies to strengthen the U.S. biotech industry, and the role of artificial intelligence in gaining competitive advantages. Key topics included navigating Washington politics, addressing pricing policies, and accelerating AI adoption.
- China rapidly catching up with US in biotech
China is rapidly catching up with the US in biotech capabilities, leading in manufacturing and clinical development while the US maintains an edge in talent and market translation. The US has responded with measures like restricting federal dealings with foreign biotech firms and accelerating drug research to restore leadership in clinical trials.
- China’s biotech industry sees global expansion as unstoppable, despite US pressure
China’s biotech firms are advancing global expansion despite U.S. investment restrictions and national security measures. Industry insiders describe the trend as 'irreversible,' with U.S. regulatory and non-tariff barriers cited as challenges for Chinese companies entering the American market.